{"ModuleTitle": "Company Description", "CompanyName": "Portola Pharmaceuticals, Inc.", "Symbol": "PTLA", "Address": "270 EAST GRAND AVENUE, SUITE 22, SOUTH SAN FRANCISCO, California, 94080, United States of America", "Phone": "650-244-6864", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "Portola Pharmaceuticals, Inc.\u00ae (the \"Company\" or \"we\" or \"our\" or \"us\") is a\r\nbiopharmaceutical company focused on the development and commercialization of\r\nnovel therapeutics in the areas of thrombosis, other hematologic diseases and\r\ninflammation for patients who currently have limited or no approved treatment\r\noptions. Our headquarters is located in South San Francisco, California.\r\nOur lead product is Andexxa [coagulation factor Xa (recombinant),\r\ninactivated-zhzo] which we are marketing under the brand name of Ondexxya in\r\nEurope. Andexxa is the first and only antidote approved by the U.S. Food and\r\nDrug Administration (\"FDA\") and the European Commission (\"EC\") for patients\r\ntreated with rivaroxaban or apixaban, when reversal of anticoagulation is needed\r\ndue to life-threatening or uncontrolled bleeding.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f28%2f0001628280-20-002568.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Glenn Brame", "title": "Chief Technical Operations Officer & Executive VP"}, {"name": "J. Scott Garland", "title": "President, Chief Executive Officer & Director"}, {"name": "Jeff Myers", "title": "Vice President-Medical Affairs"}, {"name": "Mardi C. Dier", "title": "CFO, Chief Business Officer & Executive VP"}, {"name": "Pamela B. Conley", "title": "Senior Vice President-Research"}, {"name": "Rajiv Patni", "title": "Chief Medical Officer & Executive Vice President"}], "Number_of_employees": [], "Subsidiaries": ["Portola Pharma", "Pharma U"]}